A Supreme Court headline is easy to read as a final buzzer. For people with a Roundup case already on file, it landed more like a starting gun for a second argument — this one over whether the thousands of cases already in the system get to keep going. That argument is happening right now, and it turns on a distinction most of the coverage skips.
What Actually Happened After the Supreme Court Ruled?
In short: Bayer tried to convert a narrow win into a total one, and the judge overseeing the federal cases pushed back. On June 25, 2026, the Supreme Court decided Monsanto Co. v. Durnell by a 7–2 vote, holding that the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) preempts state-law failure-to-warn claims where the EPA approved a Roundup label that carried no cancer warning. Within weeks, Bayer asked the federal court managing most of the remaining lawsuits to treat that ruling as fatal to the whole proceeding.
That proceeding is the Roundup MDL — In re: Roundup Products Liability Litigation, MDL No. 2741 — before U.S. District Judge Vince Chhabria in the Northern District of California. It was created by the Judicial Panel on Multidistrict Litigation in 2016, and by mid-2026 it held roughly 3,900 pending cases (about 3,903 as of late spring, edging up over the summer). At a July 2026 status conference, Bayer argued the MDL should be dismantled: with failure-to-warn gone, the company contended, there was nothing left for the court to coordinate.
What Is an MDL — and What Would "Dismantling" It Really Do?
An MDL is a case-management tool, not a verdict and not a class action. When many people file similar federal lawsuits across the country, the Judicial Panel on Multidistrict Litigation can send them to a single judge for coordinated pretrial work — shared discovery, common expert rulings, and test trials called bellwethers. Crucially, the individual cases stay individual. They are not merged into one claim, and each plaintiff keeps their own lawsuit.
That structure is why "dismantling the MDL" is not the same as "ending the cases." If the coordinated proceeding wound down, the surviving lawsuits would not simply disappear; under the federal MDL statute, cases that are not resolved on pretrial motions are generally remanded to the district courts where they were first filed, to be tried there. We explain how the coordinated trials inside the MDL have worked in our piece on what Roundup bellwether results mean. So the real question at the July conference was never logistics. It was whether the underlying claims can survive Durnell at all — because if they can, they have to be tried somewhere.
The Real Dispute: "Repackaged Warning Claims" vs. Design Defect
Here is the crux. Durnell preempted the failure-to-warn theory — the argument that Monsanto should have put a cancer warning on the label the EPA approved. Bayer's position at the status conference was that the claims still on file, chiefly negligence and design defect, are just the same warning argument wearing a different coat, and should fall for the same preemption reason. In the company's framing, they are "repackaged warning claims."
Plaintiffs' lawyers see two genuinely different questions. A failure-to-warn claim asks whether the label said enough. A design-defect claim asks whether the product itself was unreasonably dangerous as formulated — whether a glyphosate-based herbicide built this way should have been sold at all, regardless of what any label said. That is not a question about words on a bottle; it is a question about the chemistry in it. Reporting on the litigation after Durnell quoted plaintiff-side attorney Darin Luneckas making the practical version of the point: the easy path, failure-to-warn, is gone, so cases now have to be built on design defect and inadequate testing, which demands a different set of experts and more work. Harder is not the same as foreclosed.
This is exactly the theory The Alvarez Law Firm has led with from the start, and it is the reason the ruling did not change our approach. Alex Alvarez, our Managing Partner and a Board Certified Civil Trial Lawyer, has treated Roundup as a defective-product case — not a labeling case — because the strongest accountability argument was never that Monsanto forgot a warning; it was that the product was dangerous as designed. A claim framed that way does not rise or fall with the label the EPA happened to approve.
How Did Judge Chhabria Respond?
He declined to accept either extreme. According to reporting on the July 2026 status conference, Judge Chhabria found both sides' opening positions "unsatisfying" — Bayer's demand for wholesale dismissal on one side, and the plaintiffs' assumption that every claim automatically survives on the other. Instead of ruling that the cases are all dead or all alive, he directed the parties to grapple with the harder, claim-by-claim preemption questions through further briefing.
For anyone watching from outside, that middle path is the signal that matters. It means the court is not treating Durnell as an off-switch for the MDL. It is treating it as a ruling with defined edges that has to be applied claim by claim — which is precisely what plaintiffs pressing design-defect theories wanted, and precisely what Bayer's "it's all really a warning claim" argument was trying to avoid.
Why This Matters for People With a Diagnosis
The stakes are not abstract. The American Cancer Society estimates that about 79,320 people in the United States will be diagnosed with non-Hodgkin lymphoma in 2026 and about 19,970 will die of it, and the World Health Organization's International Agency for Research on Cancer (IARC) classified glyphosate as "probably carcinogenic to humans" (Group 2A) back in 2015. Many of the people behind the roughly 3,900 pending cases used Roundup for years before any of these court fights began.
On the medical side, Herb Borroto, M.D., J.D., our Medical-Legal Expert, reads the pathology and treatment records in a case personally — the biopsy, the subtype, the staging — because the strength of a design-defect case still rests on a credible, well-documented link between the exposure and the specific non-Hodgkin lymphoma diagnosis. The procedural drama in California does not change that clinical foundation. If anything, it raises the premium on cases that are built on evidence rather than on a label argument that the Supreme Court has now narrowed.
None of this changes the one deadline problem that quietly ends more cases than any court ruling: the statute of limitations. Whether or not the MDL is reorganized, each potential claim still runs on a filing clock that varies by state and often starts when a person knew or should have known their cancer might be tied to Roundup. We walk through that in can I still sue Monsanto for Roundup in 2026. A case cannot benefit from a favorable preemption ruling if the deadline to file it has already passed.
Frequently Asked Questions
Is my pending Roundup lawsuit dead after the Durnell ruling?
Not automatically. Monsanto Co. v. Durnell, decided June 25, 2026, held that federal pesticide law preempts state-law failure-to-warn claims where the EPA approved a Roundup label without a cancer warning. That ruling narrows one theory. It does not, by its own terms, decide claims that Roundup was defectively designed or that Monsanto was negligent in ways unrelated to the warning label. Whether any individual case continues depends on how it was pleaded and how the court applies Durnell to the remaining theories, which is exactly the question now being litigated in the federal MDL.
What is the Roundup MDL, and what would dismantling it actually mean?
An MDL, or multidistrict litigation, is a procedural tool that gathers many similar federal lawsuits before one judge for coordinated pretrial handling. The Roundup MDL, In re: Roundup Products Liability Litigation, MDL No. 2741, sits before Judge Vince Chhabria in the Northern District of California and held roughly 3,900 cases in mid-2026. An MDL is not a class action; it does not merge the cases into one claim. If the MDL were dismantled, the individual lawsuits would not necessarily vanish. Cases that survive dismissal motions are generally remanded to the federal district courts where they were originally filed for trial.
Why does Bayer call the remaining claims "repackaged warning claims"?
After Durnell foreclosed the failure-to-warn theory, Bayer argued to the MDL court that the negligence and design-defect claims still on file are really the same warning argument in a different form, and should be dismissed for the same preemption reason. Plaintiffs disagree, arguing that a design-defect claim challenges the product's formulation itself, not the adequacy of its label, and therefore is not preempted by Durnell. That characterization dispute — whether the surviving claims are genuinely independent of the label — is the heart of the current fight.
What did Judge Chhabria decide at the July 2026 status conference?
He did not adopt either side's sweeping position. According to reporting on the July 2026 status conference, Judge Chhabria found both Bayer's push for wholesale dismissal and the plaintiffs' assumption that everything survives to be unsatisfying, and directed the parties to brief the harder, claim-by-claim preemption questions rather than treat the outcome as all-or-nothing. In practical terms, that means the fate of the pending cases is being worked out through further briefing, not decided in a single stroke.
Bottom Line
A Supreme Court win narrowed one road to Bayer, and the company immediately tried to argue that every other road was really the same road. The judge who has managed these cases the longest was not willing to say so on the spot. The pending Roundup cases were not switched off in June, and they were not switched off at the July status conference; their future is being decided the slow way, claim by claim, on the question of whether a design-defect case is truly independent of the label — the theory this firm has always considered the stronger one.
Nothing here is a prediction about any particular case or a promise of any result. Whether a specific claim can move forward depends on the diagnosis, the exposure history, how the case is pleaded, the governing state law, and how the courts ultimately apply Durnell to the surviving theories — all evaluated on the individual facts. If you or a family member was diagnosed with Non-Hodgkin Lymphoma, B-cell Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma after Roundup exposure, our overview of who qualifies for a Roundup lawsuit explains what a case is built on, and the free case review is exactly that: no obligation, and no fee unless we recover for you.